Educational Event 23rd & 24th January 2013 West Suffolk Hospital Education Centre New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Welcome & Introduction Dr Christopher Browning Chair, West Suffolk Clinical Commissioning Group

The guideline has been produced to: assist GPs in identifying AF patients who are most likely to benefit from a NOAC provide advice on using the NOACs in the safest possible manner supplement the advice given by the NICE TAs, by providing expert advice and opinions of local clinicians following a detailed review of the two key trials, RE-LY and ROCKET AF

Aim: To launch the WSCCG NOACs in AF Prescribing Guideline to prescribers in the WSCCG, with the anticipation that the NOACs will subsequently be allocated ‘blue’ traffic light status to enable initiation of prescribing in primary care

By the end of this educational event prescribers should be familiar with: the mode of action of the NOACs the NICE TA Guidance for the NOACs how to calculate CHADS2, CHA2DS2-VASc & HASBLED scores the main findings of the RE-LY and ROCKET AF trials the advantages and disadvantages of the NOACs in AF how to use the WSCCG NOAC in AF Prescribing Guideline and complete the relevant checklists